Symbols

TRDA

Entrada Therapeutics·NASDAQ

--(--)

Market Open: --

--(--)

Pre-Market: --

Signals Analysis

Bullish signal 3

Bearish signal 2

Ample Liquidity

High Gross Profit Margin

Significant Net Income Decline

Revenue Beats Expectation

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About TRDA

Entrada Therapeutics, Inc.

A biopharmaceutical company that develops intracellular Endosomal Escape Vehicle therapeutics as a new class of medicines

Industry

Pharmaceutical

Established Date

09/22/2016

Listing Date

10/29/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

183

Fiscal Year Ends

12-31

Website

www.entradatx.com

Security Type

Common stock

Office address

One Design Center Place, Suite 17-500 , Boston, MA 02210

Business

Introduction

Entrada Therapeutics, Inc., was incorporated under the laws of the State of Delaware on September 22, 2016. The company aims to change the lives of patients by establishing endosomal escape vector (EEV) therapy as a novel drug, and is committed to becoming the world's foremost intracellular therapy company. The company's EEV therapies are designed to address intracellular targets that have long been considered inaccessible and undruggable. Through its proprietary, highly versatile modular EEV platform, the company is building a strong portfolio of EEV therapeutic drug candidates designed to enable effective intracellular delivery of therapeutic agents in a variety of organs and tissues and improve therapeutic indices. The company believes that the potential success of early-stage projects can be translated into the effective development of other EEV therapeutic candidates and the ability to build a portfolio in rare diseases, immunology and oncology.

Company Financials

EPS

TRDA has released its 2025 Q3 earnings. EPS was reported at -1.06, versus the expected -0.96, missing expectations. The chart below visualizes how TRDA has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

TRDA has released its 2025 Q3 earnings report, with revenue of 1.61M, reflecting a YoY change of -91.75%, and net profit of -44.13M, showing a YoY change of -214.52%. The Sankey diagram below clearly presents TRDA's revenue sources and cost distribution.